Carregant...
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors
Expression of the EGF receptors (EGFRs) is abnormally high in many types of cancer, including 25% of lung cancers. Successful treatments target mutations in the EGFR tyrosine kinase domain with EGFR tyrosine kinase inhibitors (TKIs). However, almost all patients develop resistance to this treatment,...
Guardat en:
| Publicat a: | Future Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4375777/ https://ncbi.nlm.nih.gov/pubmed/25757687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.312 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|